-
Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-09-17 Verónica Miguel, Isaac W. Shaw, Rafael Kramann
-
Polygenic scores and their applications in kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-09-13 Atlas Khan, Krzysztof Kiryluk
-
Social Connection: A Neglected Social Determinant of Health and an Opportunity to Improve Disease Management. Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-09-13 Sanya Tinaikar,Sarah J Schrauben
-
Experiences of social isolation and loneliness in chronic kidney disease: a secondary qualitative analysis Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-09 Amanda Sluiter, Rosanna Cazzolli, Allison Jaure, Nicole Scholes-Robertson, Jonathan C Craig, David W Johnson, Andrea Matus Gonzalez, Benedicte Sautenet, Ben J Smith, Karine Manera, for the SONG initiative
ial isolation, to inform strategies to increase social participation. Methods: A secondary analysis of qualitative data from the Standardized Outcomes in Nephrology (SONG) initiative dataset (36 focus groups, three Delphi surveys and seven consensus workshops) was conducted. We extracted and thematically analyzed data from patients with CKD, including those receiving hemodialysis or peritoneal dialysis
-
Symptom Burden and Altered Mineral Metabolism in Advanced Chronic Kidney Disease: Two Peas in a Pod Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-10 Orlando M. Gutiérrez
An abstract is unavailable.
-
Associations of abnormal fluid status, plasma sodium disorders, and low dialysate sodium with mortality in hemodialysis patients Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-10 Jule Pinter, Bernard Canaud, Kaitlin J Mayne, Stefano Stuard, Ulrich Moissl, Jeroen Kooman, Kitty J Jager, Nicholas C Chesnaye, Brendan Smyth, Bernd Genser
The study followed 68,196 incident hemodialysis patients from 875 dialysis clinics in 25 countries over 10 years (2010-2020) investigating dose-response patterns between cumulative exposure time of fluid overload/depletion (measured by bioimpedance spectroscopy using the Fresenius Body Composition Monitor [BCM]), abnormal plasma sodium levels, low dialysate sodium, and all-cause mortality. We calculated
-
Association of Neighborhood Social Determinants of Health with Acute Kidney Injury during Hospitalization Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-11 Lama Ghazi, Vibhu Parcha, Tomonori Takeuchi, Catherine R Butler, Elizabeth Baker, Gabriela R Oates, Lucia D Juarez, Ariann F Nassel, AKM Fazlur Rahman, Edward D. Siew, Xinyuan Chen, Orlando M Gutierrez, Javier A Neyra
lization. Methods: This is a retrospective cohort study of adults without end-stage kidney disease admitted to a large southern U.S. healthcare system from 10/2014 to 9/2017. Neighborhood SDOH measures included: 1) Socioeconomic status: Area Deprivation Index (ADI) scores, 2) Food access: Low Income Low Access (LILA) scores, 3) Rurality: Rural Urban Commuting Area (RUCA) scores, and (4) Residential
-
Phenotypes of Dialysis-Requiring Acute Kidney Injury and Associations with Mortality in a South American Population. Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-12 Conrado Lysandro R Gomes,Thais Lyra Cleto-Yamane,Patricia da Silva Fucuta,Heitor Blesa Farias,Frederico Ruzany,José Hermógenes Rocco Suassuna
BACKGROUND Acute kidney injury (AKI) is a complex syndrome typically classified into strict categories. Alternatively, it may be more accurate to consider it as an intermediate event between an initiating cause and its outcome. Therefore, we investigated the burden of clinical scenarios associated with dialysis-requiring AKI (AKI-D) using latent class analysis (LCA) and examined the etiological spectrum
-
Bioimpedance-Guided Fluid Removal in Continuous Kidney Replacement Therapy: The VENUS Randomized Clinical Trial. Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-12 Jung Nam An,Hyung Jung Oh,Sohee Oh,Harin Rhee,Eun Young Seong,Seon Ha Baek,Shin Young Ahn,Jang-Hee Cho,Jung Pyo Lee,Dong Ki Kim,Dong-Ryeol Ryu,Soyeon Ahn,Sejoong Kim
BACKGROUND Ultrafiltration with continuous kidney replacement therapy (CKRT) can be used to manage fluid balance in critically ill patients with acute kidney injury (AKI). We aimed to assess whether bioimpedance analysis (BIA)-guided volume management was more efficacious than conventional management for achieving estimated euvolemia (e-euvolemia) in CKRT-treated patients. METHODS In a multi-center
-
Ascites: Under- and Overfill: Is Amiloride the Answer? J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-11 Detlef Bockenhauer,Giulia Florio
-
Estimating GFR in Kidney Transplant Recipients: Considerations for Selecting Equations. Kidney Int. (IF 14.8) Pub Date : 2024-09-09 Krishna A Agarwal,Ogechi M Adingwupu,Hocine Tighiouart,Shiyuan Miao,Marc Froissart,Michael Mauer,Wei Yang,Vicente Torres,Martin de Borst,Goran Klintmalm,Emilio D Poggio,Peter Rossing,Ruben Velez,Anders Grubb,Andrew D Rule,Kamran Shaffi,Ashtar Chami,Andrew S Levey,Lesley A Inker
-
Comparative Effectiveness of Bisoprolol, Carvedilol, and Metoprolol Succinate in Patients with Heart Failure and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-06 Cheng-Wei Huang, Albert S. Yu, Hui Zhou, Katherine Pak, Sally F. Shaw, Jiaxiao Shi, Benjamin I. Broder, John J. Sim
An abstract is unavailable. This article is available as a PDF only.
-
Intradialytic Hypotension in the Face of Using Different Antihypertensive Medication Classes Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-09-04 Csaba P. Kovesdy
An abstract is unavailable.
-
The pathogenesis of IgA nephropathy and implications for treatment Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-09-04 Chee Kay Cheung, Suceena Alexander, Heather N. Reich, Haresh Selvaskandan, Hong Zhang, Jonathan Barratt
-
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-04 Tariq Jamal Siddiqi,David Cherney,Hasan Fareed Siddiqui,Tazeen H Jafar,James L Januzzi,Muhammad Shahzeb Khan,Adeera Levin,Nikolaus Marx,Janani Rangaswami,Jeffrey Testani,Muhammad Shariq Usman,Christoph Wanner,Faiez Zannad,Javed Butler
BACKGROUND The effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on kidney outcomes in patients with varying combinations of heart failure, chronic kidney disease, and type 2 diabetes mellitus have not been quantified. METHODS PubMed and Scopus were queried up to December 2023 for primary and secondary analysis of placebo-controlled trials of SGLT2i in patients with heart failure, chronic
-
Endothelin Receptor Antagonists Plus Sodium-Glucose Cotransporter 2 Inhibitors: Poster Child for a New ERA of Combination Therapies? J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-04 Christine P Limonte,Ian H de Boer
-
Race-and Ethnicity-Related Disparities in Predialysis Nephrology Care, Kidney Disease Education, and Home Dialysis Utilization. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-04 Ashutosh M Shukla,Grant Scheiffele,Wenxi Huang,Rebecca Campbell-Montalvo,Bian Jiang,Yi Guo,Serena Jingchuan Guo
BACKGROUND Pre-dialysis nephrology care and kidney replacement therapy (KRT)-directed education (KDE) are essential for incident home dialysis use. However, there are substantial disparities in these care parameters among patients with advanced CKD. The impact of these disparities on home dialysis underuse has not been examined. METHODS We analyzed the 2021 US Renal Database System to identify all
-
A novel mechanism of sodium and fluid retention in liver disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-09-03 Ellen F. Carney
In patients with liver disease, sodium and fluid retention is often attributed to reduced effective blood volume, which stimulates the renin–angiotensin–aldosterone system (RAAS). However, not all patients show RAAS activation. New data suggest a potential aldosterone-independent mechanism of sodium and fluid retention in liver disease. The researchers conclude that activation of ENaC by bile acids
-
Glycolysis in Peritubular Endothelial Cells and Microvascular Rarefaction in CKD. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-03 Yujie Huang,Ansheng Cong,Jinjin Li,Zhanmei Zhou,Hong Zhou,Cailing Su,Zuoyu Hu,Fan Fan Hou,Wei Cao
BACKGROUND Peritubular endothelial cell dropout leading to microvascular rarefaction is a common manifestation of chronic kidney disease (CKD). The role of metabolism reprogramming in peritubular endothelial cell loss in CKD is undetermined. METHODS Single-cell sequencing and metabolic analysis were used to characterize metabolic profile of peritubular endothelial cells from CKD patients and from CKD
-
Targeting Metabolic Reprogramming in Polycystic Kidney Disease. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-03 Alessandra Boletta
-
Opioid Prescriptions for US Patients Undergoing Long-Term Dialysis or with Kidney Transplant from 2011 to 2020. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-09-03 Paul L Kimmel,Chyng-Wen Fwu,Thomas D Nolin,Ivonne H Schulman,Shannon S Givens,Kenneth Wilkins,Susan Mendley,Debbie S Gipson,Raquel C Greer,Jenna M Norton,Kevin E Chan,Paul W Eggers
BACKGROUND Pain is important for patients with kidney failure, but opioid medication prescriptions are associated with morbidity and mortality. The Centers for Disease Control and Prevention issued opioid prescription guidelines in 2016 and 2022, associated with dramatically decreased prescription rates in the United States. It is critical to know if nationwide opioid prescription rates for patients
-
Reference-trial-informed design to explore treatment effects in trial-underrepresented subgroups Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-09-02 Paris J. Baptiste
Randomized controlled trials (RCT) are often regarded as the ‘gold standard’ of clinical evidence. However, their strict eligibility criteria can impact cohort diversity and limit the inclusion of some subgroups, including patients with comorbidities, older individuals or those from minority ethnic groups. Observational data, including data from electronic health records, can be used to bridge the
-
Targeted gene therapy for rare genetic kidney diseases. Kidney Int. (IF 14.8) Pub Date : 2024-08-31 Veenita Khare,Stephanie Cherqui
Chronic kidney disease (CKD) is one of the leading causes of mortality worldwide because of kidney failure and the associated challenges of its treatment including dialysis and kidney transplantation. About one-third of CKD cases are linked to inherited monogenic factors, making them suitable for potential gene therapy interventions. However, the intricate anatomical structure of the kidney poses a
-
The Association Between Residential Segregation and Access to Kidney Transplantation – Evidence from a Multi-State Cohort Study Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-08-26 Jasmine Berry, Aubriana Perez, Mengyu Di, Chengcheng Hu, Stephen O. Pastan, Rachel E Patzer, Jessica L Harding
(n = 42,401; 18-80 years) with ESKD initiating kidney replacement therapy (KRT) in three US States (Georgia, North Carolina, South Carolina) between January 2015 and December 2019, with follow-up through 2020, from the United States Renal Data System (USRDS). Residential segregation was defined using the racial Index of Concentration at the Extremes and classified into tertiles (predominantly Black
-
Urinary Response to Consuming Plant-Based Meat Alternatives in Persons with Normal Kidney Function: The SWAP-MEAT Pilot Trial Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-08-26 Catherine P. Ward, Matthew J. Landry, Kristen M. Cunanan, Kalani L. Raphael, Christopher C. Dant, Christopher D. Gardner, Alan C. Pao
nefits as eating whole vegetables. We hypothesized that eating plant-meat when compared with animal meat decreases dietary acid load but increases dietary phosphorus and nitrogen. Methods: SWAP-MEAT was a randomized eight-week, crossover trial (NCT03718988) of participants consuming >2 servings/day of either plant-meat or animal meat for each eight-week phase. We measured urine sulfate, ammonium, pH
-
Towards an effective obstetric nephrology care: the Mansoura experience Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-08-29 Rasha Shemies
For women with kidney disease of childbearing age, kidney care should feature discussions of pregnancy, including informed counseling and support. Health disparities between regions with different levels of income are undeniable, but special care programs aimed at the early identification and management of patients at risk can greatly decrease the magnitude of the problem.
-
Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity. Kidney Int. (IF 14.8) Pub Date : 2024-08-31 Florian Grahammer,Bernhard Dumoulin,Ramila E Gulieva,Hui Wu,Yaoxian Xu,Nurgazy Sulaimanov,Frederic Arnold,Lukas Sandner,Tomke Cordts,Abhijeet Todkar,Pierre Moulin,Wilfried Reichardt,Victor G Puelles,Rafael Kramann,Benjamin S Freedman,Hauke Busch,Melanie Boerries,Gerd Walz,Tobias B Huber
Progression of cystic kidney disease has been linked to activation of the mTORC1 signaling pathway. Yet the utility of mTORC1 inhibitors to treat patients with polycystic kidney disease remains controversial despite promising preclinical data. To define the cell intrinsic role of mTORC1 for cyst development, the mTORC1 subunit gene Raptor was selectively inactivated in kidney tubular cells lacking
-
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. (IF 14.8) Pub Date : 2024-08-30 Viknesh Selvarajah,Darren Robertson,Lars Hansen,Lutz Jermutus,Kirsten Smith,Angela Coggi,José Sánchez,Yi-Ting Chang,Hongtao Yu,Joanna Parkinson,Anis Khan,H Sophia Chung,Sonja Hess,Richard Dumas,Tabbatha Duck,Simran Jolly,Tom G Elliott,John Baker,Albert Lecube,Karl-Michael Derwahl,Russell Scott,Cristobal Morales,Carl Peters,Ronald Goldenberg,Victoria E R Parker,Hiddo J L Heerspink,
Cotadutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that may improve kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). In this phase 2b study, patients with T2D and CKD ,estimated glomerular filtration rate [eGFR] of 20 or more and under 90 mL/min per 1.73 m2 and urinary albumin-to-creatinine ratio [UACR] over 50 mg/g) were randomized
-
Where Are Patients’ Voices in Chronic Kidney Disease? Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-08-30 Despina Rüssmann, Prabir Roy-Chaudhury, Glenn M. Chertow, Patrick Gee, Cynthia Chauhan, Steven Macari, Michael Murphy, Patrick Rossignol
An abstract is unavailable. This article is available as a PDF only.
-
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney Int. (IF 14.8) Pub Date : 2024-08-30 Satoshi Miyamoto,Hiddo J L Heerspink,Dick de Zeeuw,Kota Sakamoto,Michihiro Yoshida,Masao Toyoda,Daisuke Suzuki,Takashi Hatanaka,Tohru Nakamura,Shinji Kamei,Satoshi Murao,Kazuyuki Hida,Shinichiro Ando,Hiroaki Akai,Yasushi Takahashi,Munehiro Kitada,Hisashi Sugano,Tomokazu Nunoue,Akihiko Nakamura,Motofumi Sasaki,Tatsuaki Nakatou,Kei Fujimoto,Daiji Kawanami,Takashi Wada,Nobuyuki Miyatake,Hiromi Kuramoto
Demonstrating drug efficacy in slowing kidney disease progression requires large clinical trials when targeting participants with an early stage of chronic kidney disease (CKD). In this randomized, parallel-group, open-labeled trial (CANPIONE study), we assessed the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin using the individual's change in estimated glomerular filtration
-
Chronic endothelial dopamine receptor stimulation improves endothelial function and hemodynamics in autosomal dominant polycystic kidney disease. Kidney Int. (IF 14.8) Pub Date : 2024-08-29 Audrey Dumont,Mouad Hamzaoui,Déborah Groussard,Michèle Iacob,Dominique Bertrand,Isabelle Remy-Jouet,Mélanie Hanoy,Frank Le Roy,Laurence Chevalier,Christoph Enzensperger,Hans-Dieter Arndt,Sylvanie Renet,Anaïs Dumesnil,Emilie Lévêque,Thomas Duflot,Valéry Brunel,Aurore Michel-Després,Marie-Pierre Audrézet,Vincent Richard,Robinson Joannidès,Dominique Guerrot,Jérémy Bellien
Altered polycystin-mediated endothelial flow mechanosensitivity contributes to the development of hypertension and cardiovascular complications in patients with autosomal dominant polycystic kidney disease (ADPKD). Stimulation of endothelial type 5 dopamine receptors (DR5) can acutely compensate for the endothelial consequences of polycystin deficiency, but the chronic impact of this approach must
-
Myeloperoxidase-ANCA IgG induces different forms of small vessel vasculitis based on type of synergistic immune stimuli. Kidney Int. (IF 14.8) Pub Date : 2024-08-29 Peiqi Hu,Hong Xiao,Marco A Alba,Hannah M Atkins,Shenju Gou,Yanglin Hu,John C Gomez,Corey M Jania,Jessica R Martin,Thomas E Morrison,Stephen L Tilley,Mark T Heise,Claire M Doerschuk,Ronald J Falk,J Charles Jennette
Anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis has diverse patterns of injury including microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Necrotizing and crescentic glomerulonephritis (NCGN) occurs in all syndromes and as renal limited vasculitis (RLV). Single dose intravenous ANCA IgG-specific for mouse myeloperoxidase
-
Paracellular Transport and Renal Tubule Calcium Handling: Emerging Roles in Kidney Stone Disease. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-08-29 Alan S L Yu,Joshua N Curry
The kidney plays a major role in maintenance of serum calcium concentration, which must be kept within a narrow range to avoid disruption of numerous physiologic processes that depend critically on the level of extracellular calcium, including cell signaling, bone structure, and muscle and nerve function. This defense of systemic calcium homeostasis comes, however, at the expense of the dumping of
-
Integrity of the Glomerular Filtration Barrier: The Impact of Adhesion G-Protein-Coupled Receptor F5 on Glomerular Endothelial Cells. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-08-29 Ubong S Ekperikpe,Ilse S Daehn
-
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-08-29 Xiaofan Hu, Muyin Zhang, Jing Xu, Chenni Gao, Xialian Yu, Xiao Li, Hong Ren, Weiming Wang, Jingyuan Xie
tration rate (eGFR) ≥30 mL/min/1.73 m2 despite six months of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker and treatment with obinutuzumab or rituximab were included and matched by propensity score (ratio: 1:2) based on age, sex, urine protein, eGFR, and titers of Anti-Phospholipase A2 receptor (PLA2R) antibody. The primary outcome was defined as a combination of partial or
-
Amino acid metabolism in kidney health and disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-08-28 Martine G. E. Knol, Vera C. Wulfmeyer, Roman-Ulrich Müller, Markus M. Rinschen
-
NOX2 dampens TLR7 to protect the kidneys in SLE Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-08-27 Monica Wang
Lupus nephritis (LN) is a common clinical complication in patients with systemic lupus erythematosus (SLE). A report by Mark J. Shlomchik and colleagues reveals an interplay between NADPH oxidase 2 (NOX2) and Toll-like receptor 7 (TLR7) in B cells that can modulate SLE severity, including its kidney manifestations. The researchers propose that this protection might result from NOX2-mediated inhibition
-
Microglial activation in CKD-associated cognitive decline Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-08-27 Susan J. Allison
Cognitive decline is common in patients with chronic kidney disease (CKD); however, the mechanisms linking these two conditions is unclear. New research suggests that disruption of the blood–brain barrier (BBB) by uraemic toxins may lead to microglial activation and subsequent IL-1 receptor (IL-1R)-mediated neuronal impairment. Exposure of neurons to plasma from patients with CKD did not induce their
-
The roles of hyaluronan in kidney development, physiology and disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-08-27 Ton J. Rabelink, Gangqi Wang, Johan van der Vlag, Bernard M. van den Berg
-
Mechanistic Differences between Torsemide and Furosemide. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-08-28 Veena S Rao,Zachary L Cox,Juan B Ivey-Miranda,Daniel Neville,Natasha Balkcom,Julieta Moreno-Villagomez,Daniela Ramos-Mastache,Christopher Maulion,Lavanya Bellumkonda,W H Wilson Tang,Sean P Collins,Eric J Velazquez,Robert J Mentz,F Perry Wilson,Jeffrey M Turner,Christopher S Wilcox,David H Ellison,James C Fang,Jeffrey M Testani
BACKGROUND Torsemide is proposed to have clinically important pharmacokinetic and pharmacodynamic advantages over furosemide. However, clinical outcomes did not differ in the Torsemide Comparison with Furosemide for Management of Heart Failure (TRANSFORM-HF) randomized trial. METHODS We conducted a multicenter mechanistic substudy of patients with heart failure randomized to oral furosemide or torsemide
-
Nitrofurantoin-associated crystalline and granulomatous interstitial nephritis. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Samih H Nasr,Samar M Said,Allen Flickinger
-
The Case | Obstructive acute renal failure due to acute uric acid nephrolithiasis. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Antoine Decaestecker,Amandine Ydee,Camille Metzger,Arnaud Lionet,Sarah Barbieux,Timothée Laboux,Marie-Sophie Pagniez
-
Discrepancies between transcutaneous and estimated glomerular filtration rates in rats. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Daniel Schock-Kusch,Sabine Neudecker
-
Unveiling glomerular gold in oxalate nephropathy. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Jean-Baptiste Gibier,Ellie Tang,Dominique Bazin,Kadda Medjoubi,Andrea Somogyi,Michel Daudon,Laurence Vrigneaud,Emmanuel Letavernier
-
The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Zhenjie Chen,Xuewang Li,Chao Li,Jianfang Cai,Hang Li
-
Kidney-limited TMA is common in patients with complement dysregulation. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Daan P C van Doorn,Pieter van Paassen,Sjoerd A M E G Timmermans,
-
Cardiovascular disease as a risk factor for frailty in dialysis patients. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Kah Cheong Tong,Khui Wei Wee
-
Aging kidneys reveal underlying mechanisms of endothelial dysfunction. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Ubong S Ekperikpe,Ilse S Daehn
Jiang et al. show that zinc finger FYVE-type containing 21, a Rab5 effector in glomerular endothelial cells is involved in the maintenance of glomerular filtration barrier homeostasis through the stabilization of activated endothelial nitric oxide synthase on subcellular vesicles. The study demonstrates that zinc finger FYVE-type containing 21 could modulate the levels of caveolin-1 in glomerular endothelial
-
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Carla M Nester,David L Feldman,Richard Burwick,Spero Cataland,Shruti Chaturvedi,H Terence Cook,Adam Cuker,Bradley P Dixon,Fadi Fakhouri,Sangeeta R Hingorani,Anuja Java,Nicole C A J van de Kar,David Kavanagh,Nelson Leung,Christoph Licht,Marina Noris,Michelle M O'Shaughnessy,Samir V Parikh,Flora Peyandi,Giuseppe Remuzzi,Richard J H Smith,C John Sperati,Meryl Waldman,Patrick Walker,Marina Vivarelli
The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin-associated hemolytic uremic syndrome. The
-
Improving the management of chronic kidney disease in primary care by enhancing laboratory reports with additional information and follow-up procedures. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Amit X Garg,Ann Young
Identifying people at risk for progressive chronic kidney disease and connecting them with recommended care is crucial for providing timely and optimal treatment. The ASSIST-CKD (A programme to Spread eGFR [estimated glomerular filtration rate] graph Surveillance for the early identification, Support and Treatment of people with progressive CKD [chronic kidney disease]) trial evaluated the effect of
-
The adaptive and innate immune systems coordinate for successful control of CMV infection. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Joanna M Schaenman
Previous studies of the immune control of cytomegalovirus infection have primarily focused on analysis of the traditional adaptive T-cell response. Donadeu et al. bring a new perspective through evaluation of multiple adaptive and innate immune subtypes in parallel with cytomegalovirus-specific cell-mediated immunity in a prospective cohort of kidney transplant recipients with findings validated in
-
See the power in kidney cells with ATP biosensor. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 János Peti-Peterdi,Georgina Gyarmati
Yamamoto et al. developed an exciting technical advance to examine intracellular adenosine triphosphate levels with single-cell resolution in intact living kidney tissue, including in tubular and vascular segments that lie deep under the kidney surface. The work is a significant advance on prior in vivo biosensor studies, and it allows for mechanistic investigation of alterations in cell metabolism
-
Chemical chaperones to the rescue of Alport syndrome? Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Roberto M Vanacore
Alport syndrome is a hereditary kidney disease caused by collagen IV mutations that interfere with the formation and deposition of the α3α4α5 protomer into the glomerular basement membrane. In this issue, Yu et al. show that the chemical chaperone tauroursodeoxycholic acid prevented kidney structural changes and function decline in mice with a pathogenic missense Col4a3 mutation by increasing mutant
-
Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Phoom Narongkiatikhun,Petter Bjornstad
The attenuation of glomerular hyperfiltration is posited to be a principal mechanism underlying the kidney protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in diabetic kidney disease. Notably, the impact of SGLT2 inhibitors on kidney hemodynamic function has been posited to vary between type 1 and type 2 diabetes. The study by Wada et al. documents that in an animal model of
-
The unfairness of fairness creams: unveiling the toxic impact on kidneys of mercury in beauty products. Kidney Int. (IF 14.8) Pub Date : 2024-09-01 Priti Meena,Vivekanand Jha
-
The Role of Malnutrition and Psychiatric Illnesses in Olfactory Dysfunction Post-Kidney Transplantation. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-08-27 Chia-Ter Chao
-
Association of Genetically Predicted Skipping of COL4A4 Exon 27 with Hematuria and Albuminuria. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-08-27 Frida Lona-Durazo,Kohei Omachi,Damian Fermin,Felix Eichinger,Jonathan P Troost,Meei-Hua Lin,Ian R Dinsmore,Tooraj Mirshahi,Alexander R Chang,Jeffrey H Miner,Andrew D Paterson,Moumita Barua,Sarah A Gagliano Taliun
BACKGROUND Hematuria is an established sign of glomerular disease and can be associated with kidney failure, but there has been limited scientific study of this trait. METHODS Here, we combined genetic data from the UK Biobank with predicted gene expression and splicing from GTEx kidney cortex samples (n = 65) in a transcriptome-wide association study (TWAS) to identify additional potential biological
-
Authors' Reply: The Role of Malnutrition and Psychiatric Illnesses in Olfactory Dysfunction Post-Kidney Transplantation. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-08-27 Aditi Gupta
-
Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN). Kidney Int. (IF 14.8) Pub Date : 2024-08-27 Valentin Goutaudier,Richard Danger,Rusan Ali Catar,Maud Racapé,Aurélie Philippe,Michelle Elias,Marc Raynaud,Olivier Aubert,Didier Bouton,François Girardin,Éric Vicaut,Sarhan Yaiche,Jacques Demotes,Harald Heidecke,Jean-Luc Taupin,Christine Randoux-Lebrun,Mohamad Zaidan,Emmanuelle Papuchon,Hoa Le Mai,Thi-Van-Ha Nguyen,Francesc Moreso,Thierry Berney,Jean Villard,Christophe Legendre,Duska Dragun,Vassilios
Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft
-
A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry. Kidney Int. (IF 14.8) Pub Date : 2024-08-26 Julie A Vrana,Jason D Theis,Peter J Wegwerth,Surendra Dasari,Benjamin Madden,Samih H Nasr,Mary Fidler,Ellen D McPhail,Fernando C Fervenza,Sanjeev Sethi
Membranous nephropathy (MN) results from accumulation of antigen-antibody immune complexes along the subepithelial region of the glomerular basement membranes. Over the last years, 13 target antigens have been discovered and include PLA2R, THSD7A, EXT1 and EXT2, NELL1, SEMA3B, NCAM1, CNTN1, HTRA1, FAT1, PCDH7, NTNG1, PCSK6 and NDNF, accounting for 80-90% of MN antigens. MN associated with many of these